Monge Corella, SusanaHumphreys, JamesNicolay, NathalieBraeye, ToonVan Evercooren, IzaakHolm Hansen, ChristianEmborg, Hanne-DortheSacco, ChiaraMateo-Urdiales, AlbertoCastilla, JesúsMartínez-Baz, Ivánde Gier, BrechjeHahné, SusanMeijerink, HintaKristoffersen, Anja BråthenMachado, AusendaSoares, PatriciaNardone, AnthonyBacci, SabrinaKissling, EstherNunes, BaltazarVEBIS-EHR Working Group2024-05-132024-05-132024-04Influenza Other Respir Viruses. 2024 Apr;18(4):e13292.http://hdl.handle.net/20.500.12105/19372Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.engVoRhttp://creativecommons.org/licenses/by/4.0/Cohort designCOVID-19Electronic health recordsHospitalisationMulticountry studySARS-CoV-2Vaccine effectivenessCOVID-19COVID-19 VaccinesEuropean UnionHospitalizationSARS-CoV-2Vaccine EfficacyHumansAgedMaleAtribución 4.0 Internacional38654485184e1329210.1111/irv.132921750-2659Influenza and other respiratory virusesopen access